Sulfasalazine Dr (Sulfasalazine) Patent Expiration, LOE Window & CMS Spending

Sulfasalazine Dr (Sulfasalazine) by Viatris: Multi-Source Generic Molecule, 5 AB generics, $6.9M 2024 CMS Part D & Medicaid spend.

Regulatory & Reimbursement Dimension Verified Value
Consolidated SponsorViatris
FDA Application & PathwayReconciled (ANDA)
Exclusivity / Cliff HorizonMulti-Source Generic Molecule
Core Active-Ingredient LOE DateNot listed / N/A
Last Listed Patent or Exclusivity DateNot listed / N/A
Orange Book Patents (*PED Extensions)0 patents (0 *PED)
Active AB-Rated Generic Competitors5
2024 CMS Total Public Spend$6.9M
2024 Medicare Part D Spend$5.9M
2024 Medicaid Spend$928K
Reported Wholesale Price Change (CA SB 17)0 statutory filings in 2023 to 2026 panel

Related Filings Across Meru Platforms

Verified cross-ledger federal filings for Viatris across sibling Meru public-data platforms.